Pancreatic Cancer Research

ResearcherUniversity of CambridgeActive in the last 2 years

Douglas T. Fearon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0612-0495; OpenAlex author ID A5085595853. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 10

  1. Signal peptide-independent secretion of keratin-19 by pancreatic cancer cells. Last author DOI 10.1073/pnas.2426218122↗
  2. Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-024-01790-y↗
  3. Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer. Last author DOI 10.1073/pnas.2403917121↗
  4. Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens. Last author DOI 10.1172/jci.insight.172449↗
  5. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Co-author DOI 10.1038/s41586-020-2229-5↗
  6. Pancreatic cancer cells assemble a CXCL12-keratin 19 coating to resist immunotherapy Last author DOI 10.1101/776419↗
  7. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Last author DOI 10.1126/science.aao4908↗
  8. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Co-author DOI 10.1038/nature24462↗
  9. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  10. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Last author DOI 10.1073/pnas.1320318110↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Philip Moresco · 5 shared papers, 2019–2025 · strength 1.01
  2. David Arthur Tuveson · 4 shared papers, 2013–2025 · strength 0.47
  3. Jiayun Li · 2 shared papers, 2019–2024 · strength 0.45
  4. Mikala Egeblad · 3 shared papers, 2017–2024 · strength 0.29
  5. Min Yao · 2 shared papers, 2019–2023 · strength 0.24
  6. Matthew John Weiss · 2 shared papers, 2019–2023 · strength 0.24
  7. Christopher R. Vakoc · 1 shared paper, 2024 · strength 0.16
  8. Camila dos Santos · 1 shared paper, 2024 · strength 0.16
  9. David L Spector · 1 shared paper, 2024 · strength 0.16
  10. Damianos S. Skopelitis · 1 shared paper, 2024 · strength 0.16
  11. Ledong Wan · 1 shared paper, 2024 · strength 0.16
  12. Yunus Sahin · 1 shared paper, 2024 · strength 0.16
  13. Diogo Maia-Silva · 1 shared paper, 2024 · strength 0.16
  14. Adrian R. Krainer · 1 shared paper, 2024 · strength 0.16
  15. Patrick Cunniff · 1 shared paper, 2024 · strength 0.16
  16. Divyesh V. Sejpal · 1 shared paper, 2023 · strength 0.14
  17. Daniel A. King · 1 shared paper, 2023 · strength 0.14
  18. Christine A. Iacobuzio–Donahue · 2 shared papers, 2017–2018 · strength 0.12
  19. Zhikai Wang · 1 shared paper, 2019 · strength 0.09
  20. Jaclyn Frances Hechtman · 1 shared paper, 2019 · strength 0.09
  21. Anthony C. Venida · 1 shared paper, 2020 · strength 0.09
  22. Douglas E. Biancur · 1 shared paper, 2020 · strength 0.09
  23. Seth J. Parker · 1 shared paper, 2020 · strength 0.09
  24. Joao A Paulo · 1 shared paper, 2020 · strength 0.09
  25. Suprit Gupta · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.